Biogen

Stran & Company Appoints Ian Thomas Wall as Chief Information Officer

Retrieved on: 
Thursday, January 4, 2024
Commercial software, Associate, Tufts University, Bentley University, Senior, Biogen, Liberal arts education, ITIL, Digital transformation, Intelligence, University, Vertex Pharmaceuticals, Harvard University, Interim, Growth, Risk management, SWAG, Information technology

Quincy, MA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ: SWAG; SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, announces that it has appointed Ian Thomas Wall as its Chief Information Officer.

Key Points: 
  • Quincy, MA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ: SWAG; SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, announces that it has appointed Ian Thomas Wall as its Chief Information Officer.
  • “We are thrilled to welcome Ian as our new Chief Information Officer given his impressive professional history and demonstrated ability to leverage technology to enhance operations, improve efficiency, and strengthen the customer experience,” commented Andy Shape, Chief Executive Officer of Stran.
  • At Digital Radius, Mr. Wall was responsible for overseeing all enterprise information technology and acted as a chief information officer for its clients and managing project teams.
  • Mr. Wall holds a BA in Liberal Arts from the University of Massachusetts Amherst and an MS in Science & Engineering Management (MSEM) from Tufts University.

Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Conference, Science, Partnership, Royal college, Research and development, Bleeding, Cardiff University, Translational medicine, Trial of the century, Doctor of Philosophy, Research, Therapy, Innovation, University, Chairperson, Factor VII deficiency, Von Willebrand disease, Biogen

The company also announced CEO Benny Sorensen, MD, PhD, will present an update on Hemab's progress and outlook for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, at 4:30 PM PST/7:30 PM EST.

Key Points: 
  • The company also announced CEO Benny Sorensen, MD, PhD, will present an update on Hemab's progress and outlook for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, at 4:30 PM PST/7:30 PM EST.
  • We welcome Akshay and the expertise he brings to Hemab and its mission."
  • "Akshay joins our Board at a time when his experience leading translational research, clinical development and delivering regulatory success will be invaluable," said Dr. Sorensen.
  • "I am thrilled to have his partnership and to bring his passion for science and commitment to building people-focused cultures to Hemab."

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024
Conference, Wills Eye Hospital, Biotechnology, Paratriathlon, Medicine, Nightstar, Acquisition, Eli Lilly, Alcon, Retina, ProQR, Drug, MD, Ocriplasmin, Merck & Co., Stargardt disease, Abstract, Protein splicing, Laboratory, Stargardt, Merck, Gene, Genetic, Growth, Biogen, Pharmaceutical industry

BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.

Key Points: 
  • BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.
  • Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
  • Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics NV as its Chief Medical Officer.
  • Aniz Girach, MD., Chief Medical Officer of SpliceBio, commented: "Inherited retinal diseases are a heterogenous group of rare diseases that can lead to severe visual disability and blindness, affecting approximately 5.5 million people worldwide.

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024
Conference, Wills Eye Hospital, Biotechnology, Paratriathlon, Medicine, Nightstar, Acquisition, Eli Lilly, Alcon, Retina, ProQR, Drug, MD, Ocriplasmin, Merck & Co., Stargardt disease, Abstract, Protein splicing, Laboratory, Stargardt, Merck, Gene, Genetic, Growth, Biogen, Pharmaceutical industry

BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.

Key Points: 
  • BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.
  • Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
  • Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics NV as its Chief Medical Officer.
  • Aniz Girach, MD., Chief Medical Officer of SpliceBio, commented: "Inherited retinal diseases are a heterogenous group of rare diseases that can lead to severe visual disability and blindness, affecting approximately 5.5 million people worldwide.

LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Phase, Alzheimer's disease, Dementia, Biogen, BIIB, Disease, Clinical trial, Lecanemab, Scrip, Pathology, Eisai, Pharmaceutical industry

The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.

Key Points: 
  • The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.
  • The award for Clinical Advance of the Year recognizes the success of a new drug product in a clinical trial that is expected to lead to an advance in healthcare.
  • It was awarded for the success of the Phase III Clarity AD study of LEQEMBI.
  • Eisai and Biogen deeply appreciate the cooperation of people living with AD and healthcare professionals who participated in LEQEMBI's clinical studies.

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

Retrieved on: 
Tuesday, December 19, 2023
Marketing, Biogen, European Commission, BIIB, Sale, Dimethyl fumarate, Civil service commission

CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.
  • In reaching this decision, the European Commission affirmed that Biogen is entitled to full data protection and marketing protection for TECFIDERA.
  • Biogen welcomes the actions of the European Commission, which confirm the laws governing data exclusivity and marketing protection.
  • Biogen has sufficient supply of TECFIDERA to supply the entire European market.

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

Retrieved on: 
Friday, December 15, 2023
Part, Spasm, European Commission, Food, Part Two, EMA, FDA, Diarrhea, Biogen, BIIB, European, Headache, Fatigue, Ageing, FA, Nausea, Civil service commission, Ataxia, Appetite, European Medicines Agency, Back pain, Omaveloxolone, Committee, Patient, Safety, Disability studies, Vomiting, CHMP, Pharmaceutical industry

If approved by the European Commission (EC), SKYCLARYS will be the first treatment authorized within the European Union for this rare, genetic, progressive neuromuscular disease.1 If approved, omaveloxolone will be marketed as SKYCLARYS.

Key Points: 
  • If approved by the European Commission (EC), SKYCLARYS will be the first treatment authorized within the European Union for this rare, genetic, progressive neuromuscular disease.1 If approved, omaveloxolone will be marketed as SKYCLARYS.
  • Improvements across subscales of mFARS, including upright stability, lower limb coordination, ability to swallow and upper limb coordination, were also observed in patients treated with SKYCLARYS compared to placebo.
  • The most common side effects are increased liver enzymes, decreased weight and appetite, nausea, vomiting, diarrhea, headache, fatigue, oropharyngeal and back pain, muscle spasms, and influenza.
  • The CHMP’s recommendation for SKYCLARYS will now be reviewed by the EC for marketing authorization in the European Union with a final decision expected in the first quarter of 2024.

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023
Walking, Pregnancy, Theft, PPD, Risk, Vitamin, Benzodiazepine, Breast milk, Tell, CIV, Woman, Grammatical mood, OBGYN, Medical research, Hope, Biogen, Capsule, BIIB, Health, Physician, Alertness, Sage, Therapy, Dizziness, Mental health, Behavior, Insurance, Confusion, CNS, Pharmacy, Medicaid, Patient, Diagnosis, Central nervous system, Somnolence, Pharmaceutical industry

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced ZURZUVAE™ (zuranolone) 50 mg (two 25 mg capsules per day) CIV is now available by prescription for the treatment of postpartum depression (PPD) for adults in the United States, with product already at specialty pharmacies and delivered to patients. ZURZUVAE is the first and only oral, 14-day treatment course for adults with PPD that can provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3.

Key Points: 
  • “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Retrieved on: 
Monday, December 11, 2023
Dexmedetomidine, Cardiology, Agitation, FDA, Roche, Actelion, Reata Pharmaceuticals, GSK, Pfizer, IND, Adamas, Medicine, Physician, University, Mount Sinai School, Schizophrenia, Doctor of Philosophy, MEK, Journal of Clinical Pathology, Intermittent explosive disorder, GSK plc, New product development, Caregiver, EMA, Therapy, Patient, Intelligence, Development, Senior, DSM-IV codes, Bipolar disorder, Sanofi, Royal college, Acquisition, Prostate cancer, Clinical trial, Biogen, Pharmaceutical industry

NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates.

Key Points: 
  • Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product Development and Medical Officer of BioXcel Therapeutics.
  • Additionally, Rajiv Patni, M.D., has been appointed to the newly created position of Strategic Clinical Advisor to the BioXcel Therapeutics Chief Executive Officer and Board of Directors.
  • Prior to joining BioXcel Therapeutics, Dr. O’Neill held senior leadership roles at several leading global pharmaceutical companies, including Sanofi, Genentech, and GlaxoSmithKline.
  • “I look forward to working with the BioXcel leadership team in continuing to address the unmet medical needs of patients and caregivers and advance the Company’s product-development goals.”

Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer

Retrieved on: 
Monday, November 27, 2023
Family, Research, Acquisition, Economics, Computer engineering, Intercept Pharmaceuticals, Health, Lazard, Cancer, Intercept, Business development, DSM-IV codes, Citigroup, Biogen, PCF

Sen was a visionary leader who inspired us all with his passion, dedication, and unwavering commitment to improving patient care through scientific innovation.

Key Points: 
  • Sen was a visionary leader who inspired us all with his passion, dedication, and unwavering commitment to improving patient care through scientific innovation.
  • Our thoughts and prayers are with his family and loved ones during this difficult time,” said David Fellows, Chairman of the Board of Terns.
  • Prior to joining Terns in August 2020, Mr. Sundaram was the Chief Financial Officer of Nightstar Therapeutics plc, a clinical-stage gene therapy company, until it was acquired by Biogen in 2019.
  • Prior to Nightstar, Mr. Sundaram served in a variety of positions at Intercept Pharmaceuticals, Inc., including most recently as its Vice President and Head of Business Development.